Tominersen is under clinical development by F. Hoffmann-La Roche and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Tominersen’s likelihood of approval (LoA) and phase transition for Huntington Disease took place on 21 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tominersen Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Tominersen (RG-6042) is under development for the treatment of Huntington's disease. The drug candidate is administered through intrathecal route. It is a chimeric 2'-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA. It is based on antisense technology and brain shuttle technology. It is a new molecular entity (NME) and acts by targeting HTT.
F. Hoffmann-La Roche overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
Quick View Tominersen LOA Data
|Highest Development Stage|